MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Andreas Argyrides - Wedbush Securities Olivia Brayer - Cantor Fitzgerald Steven Lichtman - Oppenheimer and Company Oren Livnat - H.C. Wainwright Thomas Smith - Leerink Partners Anthony Petrone - Mizuho Group Operator Good afternoon and welcome to MannKind Corporation 2023 Fourth Qu ...

For the quarter ended December 2023, MannKind (MNKD) reported revenue of $58.47 million, up 62.2% over the same period last year. EPS came in at $0.02, compared to -$0.07 in the year-ago quarter.The reported revenue represents a surprise of +11.67% over the Zacks Consensus Estimate of $52.36 million. With the consensus EPS estimate being -$0.01, the EPS surprise was +300.00%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

MannKind (MNKD) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.02 per share when it actually produced earnings of $0.02, delivering a surprise of 200%.Over the last four quarters, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of incorpora ...

EXHIBIT 99.1 mannkind MANNKIND CORPORATION REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at December 31, 2023 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. February 27, 2024 (Globe Newswire) — MannKind Corporat ...

Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetesPrimary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled 305 patients living with type 1 ...

MirageC/Moment via Getty Images Evaluating MannKind's Position in Light of Recent Tyvaso DPI Sale MannKind (NASDAQ:MNKD) is down 14% since my "Buy" recommendation in October. This is in spite of favorable advancements. In January, MannKind sold 10% of its Tyvaso DPI, developed in collaboration with United Therapeutics (UTHR), for $150 million upfront (with the potential for an additional $50 million depending on Tyvaso DPI revenue) to Sagard Healthcare. The milestone payment is outlined as follows: $50 ...

MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Ron Feiner - Oppenheimer Oren Livnat - H.C. Wainwright Andreas Argyrides - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being rec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction o ...

MannKind Corporation (NASDAQ:MNKD) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steve Binder - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Company Olivia Brayer - Cantor Anish Nikhanj - RBC Capital Market Thomas Smith - Leerink Partners Oren Livnat - H.C. Wainwright Anthony Petrone - Mizuho Operator Good afternoon and welcome to MannKind Corporation 2023 Second Quarter Financial Results Ear ...